Human Neural Larva Migrants Caused by *Ophidascaris robertsi* Ascarid


We describe a case in Australia of human neural larva migrants caused by the ascarid *Ophidascaris robertsi*, for which Australian carpet pythons are definitive hosts. We made the diagnosis after a live nematode was removed from the brain of a 64-year-old woman who was immunosuppressed for a hypereosinophilic syndrome diagnosed 12 months earlier.

*Ophidascaris* species are nematodes exhibiting an indirect lifecycle; various genera of snakes across the Old and New Worlds are definitive hosts. *O. robertsi* nematodes are native to Australia, where the definitive hosts are carpet pythons (*Morelia spilota*). The adult nematodes inhabit the python’s esophagus and stomach and shed their eggs in its feces. Eggs are ingested by various small mammals, in which larvae establish, serving as intermediate hosts (1). Larvae migrate to thoracic and abdominal organs (1–3) where, particularly in marsupials, the third-stage larvae may reach a considerable length (7–8 cm), even in small hosts (3,4). The lifecycle concludes when pythons consume the infected intermediate hosts (3). Humans infected with *O. robertsi* larvae would be considered accidental hosts, although human infection with any *Ophidascaris* species has not previously been reported. We report a case of human neural larva migrants caused by *O. robertsi* infection.

**The Study**

A 64-year-old woman from southeastern New South Wales, Australia, was admitted to a local hospital in late January 2021 after 3 weeks of abdominal pain and diarrhea, followed by dry cough and night sweats. She had a peripheral blood eosinophil count (PBEC) of 9.8 × 10⁹ cells/L (reference range <0.5 × 10⁹ cells/L), hemoglobin 99 g/L (reference range 115–165 g/L), platelets 617 × 10⁹ cells/L (reference range 150–400 × 10⁹ cells/L), and C-reactive protein (CRP) 102 mg/L (reference range <5 mg/L). Her medical history included diabetes mellitus, hypothyroidism, and depression. She was born in England and had traveled to South Africa, Asia, and Europe 20–30 years earlier. She was treated for community-acquired pneumonia with doxycycline and had not recovered fully.

A computed tomography (CT) scan revealed multifocal pulmonary opacities with surrounding ground-glass changes, as well as hepatic and splenic lesions. Bronchoalveolar lavage revealed 30% eosinophils without evidence of malignancy or pathogenic microorganisms, including helminths. Serologic testing was negative for *Strongyloides*. Autoimmune disease screening results were negative. The patient’s diagnosis was eosinophilic pneumonia of unclear etiology; she began taking prednisolone (25 mg/d) with partial symptomatic improvement.

Three weeks later, she was admitted to a tertiary hospital with recurrent fever and a persistent cough while on prednisolone. PBEC was 3.4 × 10⁹ cells/L and CRP was 68.2 mg/L. CT scans revealed persistent hepatic and splenic lesions and migratory pulmonary opacities (Figure 1, panels A, B). The pulmonary and hepatic lesions were 18F-fluorodeoxyglucose–avid on positive emission tomography scan. Lung biopsy specimen was consistent with eosinophilic pneumonia but not with eosinophilic granulomatosis with polyangiitis (EGPA) (Figure 1, panel C). Bacterial, fungal, and mycobacterial cultures were negative.

Author affiliations: Canberra Health Services, Canberra, Australian Capital Territory, Australia (M. Hossain, K.J. Kennedy, H.L. Wilson, C.A. Hawkins, H. Bandi, S.N. Senanayake); Australian National University, Canberra (K.J. Kennedy, C.A. Hawkins, H. Bandi, S.N. Senanayake); Commonwealth Scientific and Industrial Research Organization Australian Capital Territory, Canberra (D. Spratt); University of Melbourne, Melbourne, Victoria, Australia (A. Koehler, R.B. Gasser); University of Sydney, Sydney, New South Wales, Australia (J. Šlapeta); The University of Sydney Institute for Infectious Diseases, Sydney (J. Šlapeta)

DOI: http://doi.org/10.3201/eid2909.230351
Neural Larva Migrans with *O. robertsi* Ascarid

Echinococcus, Fasciola, and Schistosoma antibodies were not detected; concentrated and fixed-stain techniques did not reveal parasites on fecal specimens.

We detected a monoclonal T-cell receptor gene rearrangement, suggesting T-cell driven hypereosinophilic syndrome (HES). Other hematologic and vasculitis investigations were unremarkable. HES treatment began with prednisolone (50 mg/d) and mycophenolate (1 g 2×/d). Because of her travel history, possibility of false-negative Strongyloides serology, and increased immunosuppression, she received ivermectin (200 µg/kg orally) for 2 consecutive days and a repeat dose after 14 days.

A CT scan in mid-2021 showed improvement in the pulmonary and hepatic lesions but unchanged splenic lesions. PBEC was 0.76 × 10⁹ in September 2021. We added mepolizumab (interleukin-5 monoclonal antibody, 300 mg every 4 wk) in January 2022 because we were unable to reduce the prednisolone below 20 mg daily without a flare of respiratory symptoms. When PBEC returned within normal range, we tapered the prednisolone dose.

During a 3-month period in 2022, the patient experienced forgetfulness and worsening depression while continuing prednisolone (7.5 mg/d) and mycophenolate and mepolizumab at the same doses. PBEC was within reference range; CRP was 6.4 mg/L. Brain magnetic resonance imaging showed a 13 × 10 mm peripherally enhancing right frontal lobe lesion (Figure 2, panel A). In June 2022, she underwent an open biopsy. We noted a stringlike structure within the lesion, which we removed; it was a live and motile helminth (80 mm long, 1 mm diameter) (Figure 2, panels B, C). We performed a circumferential durotomy and...
corticotomy and found no other helminths. Histopathology of the dural tissue revealed a benign, organizing inflammatory cavity with prominent eosinophilia.

We provisionally identified the helminth as a third-stage larva of *Ophidascaris robertsi* on the basis of its distinctive red color, 3 active ascaridoid-like lips, presence of a cecum, and absence of a fully developed reproductive system, in the context of the known epidemiologic distribution of this species. The head and tail were preserved at the Australian National Wildlife Collection (W/LHC no. N5758). Small segments underwent independent PCR-based sequencing targeting the cytochrome oxidase c subunit 1 (cox1) (5,6) at the University of Sydney and the second internal transcribed spacer (ITS) 2 of nuclear ribosomal DNA (7) at the University of Melbourne. Both sequencing results provided >99.7% sequence match to *Ophidascaris* (formerly *Ampikecum*) *robertsi* isolates in the National Biotechnology Information and in-house databases (Appendix, https://wwwnc.cdc.gov/EID/article/29/9/23-0351-App1.pdf).

A progress CT scan revealed resolution of pulmonary and hepatic lesions but unchanged splenic lesions. The patient received 2 days of ivermectin (200 μg/kg/d) and 4 weeks of albendazole (400 mg 2×/d). She was given a weaning course of dexamethasone (starting 4 mg 2×/d) over 10 weeks, while all other immunosuppression was discontinued. Six months after surgery (3 months after ceasing dexamethasone), the patient’s PBEC remained normal. Neuropsychiatric symptoms had improved but persisted.

**Conclusions**
The patient in this case resided near a lake area inhabited by carpet pythons. Despite no direct snake contact, she often collected native vegetation, warri-gal greens (*Tetragonia tetragonioides*), from around the lake to use in cooking. We hypothesized that she inadvertently consumed *O. robertsi* eggs either directly from the vegetation or indirectly by contamination of her hands or kitchen equipment.

The patient’s clinical and radiologic progression suggests a dynamic process of larval migration to multiple organs, accompanied by eosinophilia in blood and tissues, indicative of visceral larva migrans syndrome. We suspect that the splenic lesions are a separate pathology because they remained stable and were not PET avid, unlike the pulmonary and hepatic lesions.

This case highlights the difficulty in obtaining a suitable specimen for parasitic diagnosis and the challenging management decisions regarding immunosuppression in the presence of potentially life-threatening HES. Although visceral involvement is common in animal hosts, the invasion of the brain by *Ophidascaris* larvae had not been reported previously. The patient’s immunosuppression may have enabled the larvae to migrate into the central nervous system (CNS). The growth of the third-stage larva in the human host is notable, given that previous experimental studies have not demonstrated larval development in domesticated animals, such as sheep, dogs, and cats, and have shown more restricted larval growth in birds and nonnative mammals than in native mammals (4).

After we removed the larva from her brain, the patient received anthelmintics and dexamethasone to address potential larvae in other organs. *Ophidascaris* larvae are known to survive for long periods in animal hosts; for example, laboratory rats have remained infected with third-stage larvae for ≥4 years (4). The rationale for ivermectin and albendazole was based on data from the treatment of nematode infections in snakes and humans (8,9). Albendazole has better penetration into the CNS than ivermectin (10). Dexamethasone has been used in other human nematode and tapeworm infections to avoid deleterious inflammatory CNS responses following treatment (11).

In summary, this case emphasizes the ongoing risk for zoonotic diseases as humans and animals interact closely. Although *O. robertsi* nematodes are endemic to Australia, other *Ophidascaris* species infect snakes elsewhere, indicating that additional human cases may emerge globally.

**Acknowledgments**
We thank Mitali Fadia and Sophie Hale for their assistance.

**About the Author**
Dr. Hossain is an infectious diseases physician in Australia. Her primary research interest is in parasitology.

**References**


Address for correspondence: Sanjaya N. Senanayake, Infectious Diseases Unit, Canberra Health Services, The Canberra Hospital, Yamba Dr, Garran, Australian Capital Territory, Postcode 2605, Australia; email: sanjaya.senanayake@anu.edu.au

---

**February 2023**

**Emerging Pathogens**

- Infant Botulism, Israel, 2007–2021
- Crimean-Congo Hemorrhagic Fever, Spain, 2013–2021
- *Streptococcus dysgalactiae* Bloodstream Infections, Norway, 1999–2021
- Changing Disease Course of Crimean-Congo Hemorrhagic Fever in Children, Turkey
- Relationship between Telework Experience and Presenteeism during COVID-19 Pandemic, United States, March–November 2020
- Circovirus Hepatitis Infection in Heart-Lung Transplant Patient, France
- Incidence and Transmission Dynamics of *Bordetella pertussis* Infection in Rural and Urban Communities, South Africa, 2016–2018
- Influence of Landscape Patterns on Exposure to Lassa Fever Virus, Guinea
- Increased Multidrug-Resistant *Salmonella enterica* Serotype 4,[5],12:i:- Infections Associated with Pork, United States, 2009–2018
- Novel Prion Strain as Cause of Chronic Wasting Disease in a Moose, Finland
- Novel Species of *Brucella* Causing Human Brucellosis, French Guiana
- Penicillin and Cefotaxime Resistance of Quinolone-Resistant *Neisseria meningitidis* Clonal Complex 4821, Shanghai, China, 1965–2020
- Molecular Detection of *Candidatus Orientia chuto* in Wildlife, Saudi Arabia
- Age-Stratified Model to Assess Health Outcomes of COVID-19 Vaccination Strategies, Ghana
- Early Introduction and Community Transmission of SARS-CoV-2 Omicron Variant, New York, New York, USA
- Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection
- Longitudinal Analysis of Electronic Health Information to Identify Possible COVID-19 Sequelae
- (Mis)perception and Use of Unsterile Water in Home Medical Devices, PN View 360+ Survey, United States, August 2021
- Neoehrlichiosis in Symptomatic Immunocompetent Child, South Africa
- Successful Drug-Mediated Host Clearance of *Batrachochytrium salamandrivorans*
- Powassan Virus Lineage I in Field-Collected *Dermacentor variabilis* Ticks, New York, USA
- Bartonella spp. and Typhus Group Rickettsiae among Persons Experiencing Homelessness, São Paulo, Brazil

To revisit the February 2023 issue, go to: https://wwwnc.cdc.gov/eid/articles/issue/29/2/table-of-contents